Curis

CRIS · United States

Share price · CRIS

$0.61-1.09 (-63.86%) 3M

close as of 2026-11-18 · 24h delayed · vol 10.6M (1.2x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when CRIS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 17 Nov 2026+24.3%
  2. 13 Nov 2026-22.2%
  3. 9 Nov 2026-23.0%
  4. 4 Nov 2026+55.5%

    Nothing announced by CRIS that day or the session before.

  5. 29 Oct 2026+20.8%
  6. 16 Oct 2026-19.9%
  7. 15 Oct 2026-15.3%
  8. 6 Jul 2026+1613.8%
  9. 29 Jun 2026+37.7%
  10. 26 Jun 2026+56.0%

Share of unusual movement by asset

For each asset, the share of CRIS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Emavusertib
events and moves
2599%
Other company news (earnings, financing, releases naming no asset)—0%
Sessions with no dated event—1%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2
IRAK4Small molecule
Acute Myeloid LeukemiaNon-Hodgkin Lymphoma
Relapsed/Refractory Acute Myeloid Leukemia, Primary Central Nervous System Lymphoma

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
July 2027 (1)
EmavusertibPhase 1/2Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma …
Est. primary completion 2027-07 · NCT03328078 · CT.gov ↗
What to watch
November 2027 (1)
EmavusertibPhase 2Chronic Lymphocytic Leukemia, B-cell Malignancies
Est. primary completion 2027-11 · NCT07271667 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3——$5.6M$8.1M-$5.8M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0$6.7M$5.6M+ <$0.1M short-term inv.$8.6M-$9.7M operating cash flowreport ↗
2026-Q1$0$6.5M$16M$24M-$9.0M operating cash flowreport ↗
2025-Q3$3.2M$6.4M$9.6M+ $0.1M short-term inv.$7.7M-$5.6M operating cash flowreport ↗
2025-Q2$2.8M$7.5M$11M$8.6M-$8.0M operating cash flowreport ↗
2025-Q1$2.4M$8.5M$21M+ <$0.1M short-term inv.$11M-$7.3M operating cash flowreport ↗
2024-Q3$2.9M$9.7M$21M+ $0 short-term inv.$10M-$5.9M operating cash flowreport ↗
2024-Q2$2.5M$10M$11M+ $18M short-term inv.$12M-$11M operating cash flowreport ↗
2024-Q1$2.1M$9.6M$31M+ $11M short-term inv.$12M-$13M operating cash flowreport ↗
2023-Q3$2.8M$10M$25M+ $44M short-term inv.$12M-$8.2M operating cash flowreport ↗
2023-Q2$2.2M$10M$20M+ $44M short-term inv.$12M-$7.9M operating cash flowreport ↗
2023-Q1$2.3M$9.1M$32M+ $40M short-term inv.$12M-$12M operating cash flowreport ↗
2022-Q3$2.8M$11M$30M+ $69M short-term inv.$13M-$13M operating cash flowreport ↗
2022-Q2$2.4M$12M$35M+ $73M short-term inv.$16M-$12M operating cash flowreport ↗
2022-Q1$2.1M$11M$19M+ $102M short-term inv.$16M-$17M operating cash flowreport ↗
2021-Q3$3.0M$8.6M$54M+ $76M short-term inv.$11M-$9.6M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$9.4M$28M$5.6M+ <$0.1M short-term inv.$1.9M-$27M operating cash flowreport ↗

For fiscal year 2025, Curis reported revenue of $9.44M, down 13.5% YoY, and R&D spend of $28.25M, down 26.7% YoY. Cash and equivalents were $5.61M as of December 31, 2025, and the company reported a net loss of $7.58M for the year.

Operationally, Curis continued development of emavusertib, presenting updated PCNSL data from the TakeAim Lymphoma study, initial SCNSL data, and MRD conversion data from the AML triplet study. The company initiated a Phase 2 CLL study of emavusertib with zanubrutinib, sold its Erivedge royalty interest in November 2025, and closed a January 2026 private placement with gross proceeds of up to $80.8M, including initial gross proceeds of $20.2M. Curis guided that its cash position plus the January 2026 PIPE proceeds should fund planned operations into the second half of 2027.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$11M$39M$21M+ $0 short-term inv.$11M-$40M operating cash flowreport ↗
2023-FY$10M$40M$27M+ $30M short-term inv.$12M-$38M operating cash flowreport ↗
2022-FY$10M$43M$20M+ $66M short-term inv.$14M-$54M operating cash flowreport ↗
2021-FY$11M$35M$41M+ $76M short-term inv.$11M-$38M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 1 purchase ($5K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-07-07Dentzer James E · director, President & CEOAward / grant (derivative)110,090$5.29$582KForm 4
2026-07-07Zung Jonathan B. · CDOAward / grant (derivative)48,285$5.29$255KForm 4
2026-07-07Duvall Diantha · CFOAward / grant (derivative)48,285$5.29$255KForm 4
2026-07-07Borgman Anne Elizabeth · directorAward / grant (derivative)6,800$5.29$36KForm 4
2026-07-07GREENACRE MARTYN D · directorAward / grant (derivative)6,800$5.29$36KForm 4
2026-07-07Hohneker John · directorAward / grant (derivative)6,800$5.29$36KForm 4
2026-07-07KAITIN KENNETH I · directorAward / grant (derivative)6,800$5.29$36KForm 4
2026-07-07Rubin Marc · directorAward / grant (derivative)6,800$5.29$36KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 42 reporting institutions held 15.8M shares ($8.6M, 650.2% of shares outstanding).

#InstitutionSharesValue
1Bleichroeder LP3,802,329$2.1M
2Stonepine Capital Management, LLC3,726,406$2.0M
3Nantahala Capital Management, LLC2,000,000$1.1M
4SPHERA FUNDS MANAGEMENT LTD.1,994,937$1.1M
5Cable Car Capital, LP1,333,334$730K
6Dauntless Investment Group, LLC658,725$362K
7VANGUARD CAPITAL MANAGEMENT LLC374,326$205K
8RENAISSANCE TECHNOLOGIES LLC366,740$201K
9M28 Capital Management LP284,889$156K
10MORGAN STANLEY254,245$139K
11GEODE CAPITAL MANAGEMENT, LLC168,327$92K
12CM Management, LLC150,000$82K
13Focused Wealth Management, Inc109,746$60K
14CITADEL ADVISORS LLC67,018$37K
15BOOTHBAY FUND MANAGEMENT, LLC62,168$34K